Society News

During AGA’s annual Joint Committee weekend, 55 AGA members collectively attended 79 meetings with staff from the offices of their House representatives and senators, lobbying for the top concerns of gastroenterologists across the country, including:

• Continued coverage of patients through either the Affordable Care Act or another bill that has the patient’s best interests in mind. More specifically, one that provides coverage for those with pre-existing conditions and for children under their parents’ plan until 26 years of age, among many other important provisions.
• Changes in health care language that label a colonoscopy for cancer screening as “therapeutic,” which renders a large copay for patients.
• Increased funding for the NIH.

Participants shared experiences from their time on Capitol Hill in the AGA Community forum, and encouraged others to get involved. Here are some of their reasons why.

• Your voice matters: You are constituents – which translates to votes in the minds of representatives and senators – and providing face-to-face conversation with their staffers shows them that you care about your patients and their needs, explains Siddharth Singh, MD.
• Being consistent gets your foot in the door: Some staffers recognized and remembered previous Advocacy Day participants, like Peter Liang, MD, MPH. Personally connecting could lead to follow-up communication and advocacy efforts, says Sarah Streett, MD, AGAF.
• You’re indirectly (and sometimes directly) connecting with decision makers: Staff members from these offices work closely with the legislators who evaluate which policies to support or oppose. “So it’s important to come to Washington, build relationships, and make the case for our science, our specialty, and our patients,” says Kim Barrett, PhD, AGAF.
• Others could be advocating against you on the same issues: “I very strongly believe that it is important to keep letting our legislators know how we feel and what we believe in,” shares Deborah Proctor, MD, AGAF.
• It’s a rewarding experience: “Voice [your] concerns to your representatives who embrace the stories of how their decisions and policies affect your patients, practice, research, and institution,” explains Susan Ramdhaney, MD, AGAF.
• It’s a critical time to take action: With the current health care environment, gastroenterologists need to express the needs of their patients and profession, Dr. Streett explains.

View the full discussion and read updates from colleagues who visited with legislative staffers from California, New York, North Carolina, and Oregon in the forum, community.gastro.org.

Please contact [email protected].
 

[email protected]

During AGA’s annual Joint Committee weekend, 55 AGA members collectively attended 79 meetings with staff from the offices of their House representatives and senators, lobbying for the top concerns of gastroenterologists across the country, including:

• Continued coverage of patients through either the Affordable Care Act or another bill that has the patient’s best interests in mind. More specifically, one that provides coverage for those with pre-existing conditions and for children under their parents’ plan until 26 years of age, among many other important provisions.
• Changes in health care language that label a colonoscopy for cancer screening as “therapeutic,” which renders a large copay for patients.
• Increased funding for the NIH.

Participants shared experiences from their time on Capitol Hill in the AGA Community forum, and encouraged others to get involved. Here are some of their reasons why.

• Your voice matters: You are constituents – which translates to votes in the minds of representatives and senators – and providing face-to-face conversation with their staffers shows them that you care about your patients and their needs, explains Siddharth Singh, MD.
• Being consistent gets your foot in the door: Some staffers recognized and remembered previous Advocacy Day participants, like Peter Liang, MD, MPH. Personally connecting could lead to follow-up communication and advocacy efforts, says Sarah Streett, MD, AGAF.
• You’re indirectly (and sometimes directly) connecting with decision makers: Staff members from these offices work closely with the legislators who evaluate which policies to support or oppose. “So it’s important to come to Washington, build relationships, and make the case for our science, our specialty, and our patients,” says Kim Barrett, PhD, AGAF.
• Others could be advocating against you on the same issues: “I very strongly believe that it is important to keep letting our legislators know how we feel and what we believe in,” shares Deborah Proctor, MD, AGAF.
• It’s a rewarding experience: “Voice [your] concerns to your representatives who embrace the stories of how their decisions and policies affect your patients, practice, research, and institution,” explains Susan Ramdhaney, MD, AGAF.
• It’s a critical time to take action: With the current health care environment, gastroenterologists need to express the needs of their patients and profession, Dr. Streett explains.

View the full discussion and read updates from colleagues who visited with legislative staffers from California, New York, North Carolina, and Oregon in the forum, community.gastro.org.

Please contact [email protected].
 

[email protected]

During AGA’s annual Joint Committee weekend, 55 AGA members collectively attended 79 meetings with staff from the offices of their House representatives and senators, lobbying for the top concerns of gastroenterologists across the country, including:

• Continued coverage of patients through either the Affordable Care Act or another bill that has the patient’s best interests in mind. More specifically, one that provides coverage for those with pre-existing conditions and for children under their parents’ plan until 26 years of age, among many other important provisions.
• Changes in health care language that label a colonoscopy for cancer screening as “therapeutic,” which renders a large copay for patients.
• Increased funding for the NIH.

Participants shared experiences from their time on Capitol Hill in the AGA Community forum, and encouraged others to get involved. Here are some of their reasons why.

• Your voice matters: You are constituents – which translates to votes in the minds of representatives and senators – and providing face-to-face conversation with their staffers shows them that you care about your patients and their needs, explains Siddharth Singh, MD.
• Being consistent gets your foot in the door: Some staffers recognized and remembered previous Advocacy Day participants, like Peter Liang, MD, MPH. Personally connecting could lead to follow-up communication and advocacy efforts, says Sarah Streett, MD, AGAF.
• You’re indirectly (and sometimes directly) connecting with decision makers: Staff members from these offices work closely with the legislators who evaluate which policies to support or oppose. “So it’s important to come to Washington, build relationships, and make the case for our science, our specialty, and our patients,” says Kim Barrett, PhD, AGAF.
• Others could be advocating against you on the same issues: “I very strongly believe that it is important to keep letting our legislators know how we feel and what we believe in,” shares Deborah Proctor, MD, AGAF.
• It’s a rewarding experience: “Voice [your] concerns to your representatives who embrace the stories of how their decisions and policies affect your patients, practice, research, and institution,” explains Susan Ramdhaney, MD, AGAF.
• It’s a critical time to take action: With the current health care environment, gastroenterologists need to express the needs of their patients and profession, Dr. Streett explains.

View the full discussion and read updates from colleagues who visited with legislative staffers from California, New York, North Carolina, and Oregon in the forum, community.gastro.org.

Please contact [email protected].
 

[email protected]

The U.S. is facing an opioid epidemic – 91 Americans die every day from an opioid overdose. While all health care professionals should remain up to date on the risks associated with opioids, it is as important for GIs to understand how opioids can affect diverse parts of the gastrointestinal tract. Patients can experience GI symptoms and side effects related to the intake of opioids, including opioid-induced constipation (OIC), esophageal dysmotility, and delayed gastric emptying, according to a new AGA Clinical Practice Update published in the September 2017 issue of Clinical Gastroenterology and Hepatology.

Because of the common use of opioid medications to treat chronic pain, the authors recommend that physicians should first consider whether any gastrointestinal symptoms are directly related to the intake of opioids. In acute administration of opioids, symptomatic remedies should be used to counter the pharmacologic effects. For OIC, the bowel function index – a clinician assessment tool to appraise severity and responsiveness to current treatment – should be used to identify chronic OIC that is not responding to first-line therapies.

The clinical practice update also outlines:

• Pharmacologic effects of opiates in different regions of the gastrointestinal tract.
• Therapeutic uses of opioid receptor agonists and antagonists in gastroenterology.
• Prevention and treatment of OIC.

[email protected]

The U.S. is facing an opioid epidemic – 91 Americans die every day from an opioid overdose. While all health care professionals should remain up to date on the risks associated with opioids, it is as important for GIs to understand how opioids can affect diverse parts of the gastrointestinal tract. Patients can experience GI symptoms and side effects related to the intake of opioids, including opioid-induced constipation (OIC), esophageal dysmotility, and delayed gastric emptying, according to a new AGA Clinical Practice Update published in the September 2017 issue of Clinical Gastroenterology and Hepatology.

Because of the common use of opioid medications to treat chronic pain, the authors recommend that physicians should first consider whether any gastrointestinal symptoms are directly related to the intake of opioids. In acute administration of opioids, symptomatic remedies should be used to counter the pharmacologic effects. For OIC, the bowel function index – a clinician assessment tool to appraise severity and responsiveness to current treatment – should be used to identify chronic OIC that is not responding to first-line therapies.

The clinical practice update also outlines:

• Pharmacologic effects of opiates in different regions of the gastrointestinal tract.
• Therapeutic uses of opioid receptor agonists and antagonists in gastroenterology.
• Prevention and treatment of OIC.

[email protected]

The U.S. is facing an opioid epidemic – 91 Americans die every day from an opioid overdose. While all health care professionals should remain up to date on the risks associated with opioids, it is as important for GIs to understand how opioids can affect diverse parts of the gastrointestinal tract. Patients can experience GI symptoms and side effects related to the intake of opioids, including opioid-induced constipation (OIC), esophageal dysmotility, and delayed gastric emptying, according to a new AGA Clinical Practice Update published in the September 2017 issue of Clinical Gastroenterology and Hepatology.

Because of the common use of opioid medications to treat chronic pain, the authors recommend that physicians should first consider whether any gastrointestinal symptoms are directly related to the intake of opioids. In acute administration of opioids, symptomatic remedies should be used to counter the pharmacologic effects. For OIC, the bowel function index – a clinician assessment tool to appraise severity and responsiveness to current treatment – should be used to identify chronic OIC that is not responding to first-line therapies.

The clinical practice update also outlines:

• Pharmacologic effects of opiates in different regions of the gastrointestinal tract.
• Therapeutic uses of opioid receptor agonists and antagonists in gastroenterology.
• Prevention and treatment of OIC.

[email protected]

Don't forget that the end of the year is the time to keep up to date with your SVS membership dues. Invoices were emailed to all members earlier this month and are due by Dec. 31.

It's simple to pay your 2018 dues online -- and there's no need to write out a check or find a stamp! Just log on to vascular.org/payinvoice. (While you're at it, please make sure your record is up to date.) You also can make a donation to the SVS Foundation at the same time. For membership help, e-mail the SVS membership department, or call 312-334-2313

Don't forget that the end of the year is the time to keep up to date with your SVS membership dues. Invoices were emailed to all members earlier this month and are due by Dec. 31.

It's simple to pay your 2018 dues online -- and there's no need to write out a check or find a stamp! Just log on to vascular.org/payinvoice. (While you're at it, please make sure your record is up to date.) You also can make a donation to the SVS Foundation at the same time. For membership help, e-mail the SVS membership department, or call 312-334-2313

Don't forget that the end of the year is the time to keep up to date with your SVS membership dues. Invoices were emailed to all members earlier this month and are due by Dec. 31.

It's simple to pay your 2018 dues online -- and there's no need to write out a check or find a stamp! Just log on to vascular.org/payinvoice. (While you're at it, please make sure your record is up to date.) You also can make a donation to the SVS Foundation at the same time. For membership help, e-mail the SVS membership department, or call 312-334-2313

At its recent meeting, the SVS Board of Directors approved establishing a Disaster Relief Fund in response to disasters in Puerto Rico, Florida, Texas and Mexico. This Fund will support vascular surgeons and their patients who have been impacted by these extraordinary events and ensure that their commitment to vascular health is recognized in times of need.  

The Foundation leadership is working to initiate a fundraising campaign and grant application guidelines.

Members are asked to email the SVS Foundation to provide your input on the type of support that would be most helpful to vascular surgeons and their patients in these disaster areas.

At its recent meeting, the SVS Board of Directors approved establishing a Disaster Relief Fund in response to disasters in Puerto Rico, Florida, Texas and Mexico. This Fund will support vascular surgeons and their patients who have been impacted by these extraordinary events and ensure that their commitment to vascular health is recognized in times of need.  

The Foundation leadership is working to initiate a fundraising campaign and grant application guidelines.

Members are asked to email the SVS Foundation to provide your input on the type of support that would be most helpful to vascular surgeons and their patients in these disaster areas.

At its recent meeting, the SVS Board of Directors approved establishing a Disaster Relief Fund in response to disasters in Puerto Rico, Florida, Texas and Mexico. This Fund will support vascular surgeons and their patients who have been impacted by these extraordinary events and ensure that their commitment to vascular health is recognized in times of need.  

The Foundation leadership is working to initiate a fundraising campaign and grant application guidelines.

Members are asked to email the SVS Foundation to provide your input on the type of support that would be most helpful to vascular surgeons and their patients in these disaster areas.

The ACS Clinical Congress will get underway on Saturday, Oct. 21, in San Diego. The vast array of sessions, presentations, and special events can be overwhelming. The best way to manage your time is to download the meeting app and start planning to attend must-see sessions and other events. The app lets you search by day, speaker, track, and type of session, so you can build your daily schedule and connect with colleagues. The ACS Surgery News editorial team, reporters, and videographers will be on site covering many sessions and posting stories and interviews daily on the web page.

Rodrigo Cuel/Thinkstock

Don’t miss these sessions

Acoustic gunshot sensor technology impacts trauma care.

Press Conference:   TUESDAY, OCTOBER 24  - 10:30-11:00 a.m.
Location: Room 21 – San Diego Convention Center (Upper level)

~~~~

Lessons Learned from Las Vegas and other Major Intentional Mass Casualty Events.

Panel Session: TUESDAY, OCTOBER 24 – 8:00 – 9:30 a.m.

Location: 2, Upper Level of the San Diego Convention Center. 

The ACS Surgery News editorial team offers the following picks among the hundreds of panels, sessions, and scientific forums:

•PS101: Controversies in the Management of Complicated Diverticulitis (Monday, Oct. 23, 9:45 am - 11:15 am, Hall F)

•PS104: The Gut Microbiome: Implications for Surgical Complications (Monday, Oct. 23, 9:45 am - 11:15 am, Room 20D)

•PS108: Management of Axilla in Breast Cancer (Monday, Oct. 23, 9:45 am - 11:15 am, 20A)

•PS109: Cholecystectomy: From Lap Chole to Open Common Duct Exploration (Monday, Oct. 23, 11:30 am - 1:00 pm, Hall F)

•PS200: The Impossible Gallbladder: Is Cholecystectomy Always the Answer? (Tuesday, Oct. 24, 8:00 am - 9:30 am, Hall F)

•PS204: What’s New in Hospital Acquired Infections? II (Tuesday, Oct. 24, 8:00 am - 9:30 am, Room 6E)

•PS218: Ergonomics for Surgeons: Preventing Work Related Injuries (Tuesday, Oct. 24, 9:45 am - 11:15 am)

•PS302: Shared Decision Making for Treatment of Uncomplicated Appendicitis (Wednesday, Oct. 25, 8:00 am - 9:30 am, Room 20C)

•PS313: Managing Bariatric Complications: The Role of the Non-Bariatric Surgeon (Wednesday, Oct. 25, 12:45 pm - 2:15 pm, Room 20D)

•PS332: Training Surgeons for Rural Practice (Wednesday, Oct. 25, 4:15 pm - 5:45 pm, Room 20D)

•PS400: Top Hot Topics in General Surgery (Thursday, Oct. 26, 8:00 am - 9:30 am, Room 20BC)


Social media

Follow Therese Borden on Twitter for live tweets during the meeting.
 

[email protected]

On Twitter @ThereseBorden

The ACS Clinical Congress will get underway on Saturday, Oct. 21, in San Diego. The vast array of sessions, presentations, and special events can be overwhelming. The best way to manage your time is to download the meeting app and start planning to attend must-see sessions and other events. The app lets you search by day, speaker, track, and type of session, so you can build your daily schedule and connect with colleagues. The ACS Surgery News editorial team, reporters, and videographers will be on site covering many sessions and posting stories and interviews daily on the web page.

Rodrigo Cuel/Thinkstock

Don’t miss these sessions

Acoustic gunshot sensor technology impacts trauma care.

Press Conference:   TUESDAY, OCTOBER 24  - 10:30-11:00 a.m.
Location: Room 21 – San Diego Convention Center (Upper level)

~~~~

Lessons Learned from Las Vegas and other Major Intentional Mass Casualty Events.

Panel Session: TUESDAY, OCTOBER 24 – 8:00 – 9:30 a.m.

Location: 2, Upper Level of the San Diego Convention Center. 

The ACS Surgery News editorial team offers the following picks among the hundreds of panels, sessions, and scientific forums:

•PS101: Controversies in the Management of Complicated Diverticulitis (Monday, Oct. 23, 9:45 am - 11:15 am, Hall F)

•PS104: The Gut Microbiome: Implications for Surgical Complications (Monday, Oct. 23, 9:45 am - 11:15 am, Room 20D)

•PS108: Management of Axilla in Breast Cancer (Monday, Oct. 23, 9:45 am - 11:15 am, 20A)

•PS109: Cholecystectomy: From Lap Chole to Open Common Duct Exploration (Monday, Oct. 23, 11:30 am - 1:00 pm, Hall F)

•PS200: The Impossible Gallbladder: Is Cholecystectomy Always the Answer? (Tuesday, Oct. 24, 8:00 am - 9:30 am, Hall F)

•PS204: What’s New in Hospital Acquired Infections? II (Tuesday, Oct. 24, 8:00 am - 9:30 am, Room 6E)

•PS218: Ergonomics for Surgeons: Preventing Work Related Injuries (Tuesday, Oct. 24, 9:45 am - 11:15 am)

•PS302: Shared Decision Making for Treatment of Uncomplicated Appendicitis (Wednesday, Oct. 25, 8:00 am - 9:30 am, Room 20C)

•PS313: Managing Bariatric Complications: The Role of the Non-Bariatric Surgeon (Wednesday, Oct. 25, 12:45 pm - 2:15 pm, Room 20D)

•PS332: Training Surgeons for Rural Practice (Wednesday, Oct. 25, 4:15 pm - 5:45 pm, Room 20D)

•PS400: Top Hot Topics in General Surgery (Thursday, Oct. 26, 8:00 am - 9:30 am, Room 20BC)


Social media

Follow Therese Borden on Twitter for live tweets during the meeting.
 

[email protected]

On Twitter @ThereseBorden

The ACS Clinical Congress will get underway on Saturday, Oct. 21, in San Diego. The vast array of sessions, presentations, and special events can be overwhelming. The best way to manage your time is to download the meeting app and start planning to attend must-see sessions and other events. The app lets you search by day, speaker, track, and type of session, so you can build your daily schedule and connect with colleagues. The ACS Surgery News editorial team, reporters, and videographers will be on site covering many sessions and posting stories and interviews daily on the web page.

Rodrigo Cuel/Thinkstock

Don’t miss these sessions

Acoustic gunshot sensor technology impacts trauma care.

Press Conference:   TUESDAY, OCTOBER 24  - 10:30-11:00 a.m.
Location: Room 21 – San Diego Convention Center (Upper level)

~~~~

Lessons Learned from Las Vegas and other Major Intentional Mass Casualty Events.

Panel Session: TUESDAY, OCTOBER 24 – 8:00 – 9:30 a.m.

Location: 2, Upper Level of the San Diego Convention Center. 

The ACS Surgery News editorial team offers the following picks among the hundreds of panels, sessions, and scientific forums:

•PS101: Controversies in the Management of Complicated Diverticulitis (Monday, Oct. 23, 9:45 am - 11:15 am, Hall F)

•PS104: The Gut Microbiome: Implications for Surgical Complications (Monday, Oct. 23, 9:45 am - 11:15 am, Room 20D)

•PS108: Management of Axilla in Breast Cancer (Monday, Oct. 23, 9:45 am - 11:15 am, 20A)

•PS109: Cholecystectomy: From Lap Chole to Open Common Duct Exploration (Monday, Oct. 23, 11:30 am - 1:00 pm, Hall F)

•PS200: The Impossible Gallbladder: Is Cholecystectomy Always the Answer? (Tuesday, Oct. 24, 8:00 am - 9:30 am, Hall F)

•PS204: What’s New in Hospital Acquired Infections? II (Tuesday, Oct. 24, 8:00 am - 9:30 am, Room 6E)

•PS218: Ergonomics for Surgeons: Preventing Work Related Injuries (Tuesday, Oct. 24, 9:45 am - 11:15 am)

•PS302: Shared Decision Making for Treatment of Uncomplicated Appendicitis (Wednesday, Oct. 25, 8:00 am - 9:30 am, Room 20C)

•PS313: Managing Bariatric Complications: The Role of the Non-Bariatric Surgeon (Wednesday, Oct. 25, 12:45 pm - 2:15 pm, Room 20D)

•PS332: Training Surgeons for Rural Practice (Wednesday, Oct. 25, 4:15 pm - 5:45 pm, Room 20D)

•PS400: Top Hot Topics in General Surgery (Thursday, Oct. 26, 8:00 am - 9:30 am, Room 20BC)


Social media

Follow Therese Borden on Twitter for live tweets during the meeting.
 

[email protected]

On Twitter @ThereseBorden

Interventional Chest/Diagnostic Procedures

Cryobiopsy for ILD: Careful stewardship needed

Interest in transbronchial cryobiopsy has accelerated rapidly in recent years. This procedure is performed by advancing a cryoprobe into the peripheral lung via flexible bronchoscopy, where lung tissue freezes and adheres to the probe and is subsequently extracted as a cryobiopsy. The number of cryobiopsy-related publications has increased exponentially since it was described in 2009 (Babiak A, et al. Respiration. 2009;78[2]:203). This interest stems from reports of high diagnostic yields in patients with interstitial lung disease (ILD) while maintaining complication rates similar to that of conventional bronchoscopic biopsy.

Traditional bronchoscopic biopsies are notoriously insensitive; a specific diagnosis can be established in fewer than a third of cases (Sheth JS, et al. Chest. 2017;151[2]:389). As such, surgical lung biopsy continues to be recommended but is associated with significant mortality (2%) and morbidity (30%) in patients with ILD (Hutchinson JP, et al. ARJCCM. 2016;193[10]:1161). Cryobiopsy, which appears to rival surgical lung biopsy in terms of ability to contribute to a specific diagnosis, is, therefore, a highly promising alternative (Tomassetti S, et al. AJRCCM. 2016;193[7]:745).

As cryobiopsy is increasingly adopted around the world, however, troubling reports of serious complications have surfaced. Most notable is the recently reported experience of the initial 25 cases performed at the University of Pennsylvania, in which almost one in four patients suffered serious complications (DiBardino DM, et al. Ann Am Thorac Soc. 2017;14[6]:851). The authors pointed to lack of a predefined procedural protocol, as well as several choices relating to the specific technique used, including inconsistent use of fluoroscopy, lack of prophylactic bronchial blocker placement, and predominant use of laryngeal mask airways as potential contributing factors. Indeed, many variations of the basic cryobiopsy procedure have been described (Lentz RJ, et al. J Thoracic Dis. 2017;9[7]:2186), with no formal guidance or training available to inform advanced bronchoscopists interested in this procedure.

It is incumbent on the interventional pulmonology and ILD specialist communities to be responsible stewards of this promising procedure. Implementation of three parallel efforts to standardize and rigorously study this procedure should be considered as soon as possible: creation of expert consensus guidelines establishing best-practices for safe and effective biopsy technique; a training requirement before independent performance of the procedure; and creation of an international cryobiopsy registry to facilitate higher-quality research into optimal technique and outcomes. We owe this to our patients.

Robert J. Lentz, MD
NetWork Member

Fabien Maldonado, MD, FCCP
NetWork Member

Pediatric Chest Medicine

Chronic cough in children: New guidelines

A chronic cough is a common complaint among children whose parents seek medical evaluation. Chronic wet cough can indicate an underlying illness; therefore, an early diagnosis can lead to prevention of complications of the disease and improvement in quality of life.

CHEST is a leading resource in evidence and consensus-based guidelines on important topics affecting children. The most recent guidelines entitled Management of Children with Chronic Wet Cough and Protracted Bacterial Bronchitis (Chest. 2017;151(4):884-890) and Use of Management Pathways or Algorithms in Children with Chronic Cough (Chest. 2017;151(4):875-873) are updates from the 2006 CHEST guidelines on chronic cough in children.

The present updates utilized the CHEST methodological guidelines with chronic wet or productive cough and Grading of Recommendations Assessment, Development, and Evaluation framework and also performed a systematic review addressing key questions concerning the management of childhood disease for children 14 years and younger.

Guidance provided by the expert panel focused on recommendations to answer six key questions concerning the management of children 14 years and younger with a chronic wet cough unrelated to established chronic lung disease. The recommendations are:

1. Chronic cough is defined as the presence of a cough 4 weeks or longer in duration.

2. Assessment of the effect of the cough on the child and the family be undertaken as part of clinical consultation.

3. Evaluation of a chronic cough should be done with a systematic approach with pediatric-specific cough management protocols or algorithms.

4. Chest radiograph and, when age appropriate, spirometry with bronchodilator be undertaken as evaluation; tests for pertussis infection only to be performed if clinically suspected.

5. Chronic wet cough with no specific clinical features should receive antibiotics for 2 weeks targeted for common respiratory bacteria (Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis).

6. When cough persists despite 2 weeks of appropriate antibiotics, it is recommended to continue for an additional 2 weeks.

7. Additional tests (eg skin prick test, Mantoux, bronchoscopy, chest CT scan) should be individualized in accordance with the clinical setting and child’s clinical symptoms and signs.

The panel recognizes the need for prospective studies to assess current algorithms outcomes of children with chronic cough. Both articles can be found on the guidelines section of the CHEST site.

John Bishara, DO
Fellow-in-Training Member

Pulmonary Physiology, Function, and Rehabilitation

Functional imaging of the lung

Quantifying heterogeneity of ventilation and gas exchange in lung diseases remains a clinical challenge. Conventional pulmonary function test is insensitive to regional changes. The multiple inert gas elimination technique can quantify ventilation-perfusion distribution, but it requires invasive instrumentation (eg, pulmonary artery catheterization) and is not practical for clinical use. Computed tomography (CT) scans delineate spatial changes in lung structures but do not directly measure changes in ventilation and gas exchange. With its radiation, it is difficult to apply CT scanning repeatedly in patients. More recently, MR imaging techniques have been developed to directly “visualize” and quantify regional lung function (Kruger SJ, et al. J Magn Reson Imaging. 2016;43(2):295; Roos JE, et al. Magn Reson Imaging Clin N Am. 2015;23(2):217). These techniques employ inhalation of gases, such as oxygen, perfluorinated gases, and hyperpolarized ³He and ¹²⁹Xe. Hyperpolarized ³He has been studied the most; however, the dwindling supply of ³He gas and its rising cost have prevented its further development. ¹²⁹Xe has abundant supply and has emerged to be the inert gas of choice for MR imaging. Hyperpolarized ¹²⁹Xe can measure ventilation, like hyperpolarized ³He. In addition, Xe diffuses into alveolar barrier (interstitium and plasma) and red blood cells, where it exhibits distinct resonant frequency shifts that can be captured by MR. Therefore, in one test, information on pulmonary ventilation and gas transfer can be obtained. To date, the results from MR imaging studies have provided new insights into the pathophysiology of obstructive and restrictive lung diseases. With continuous development, MR imaging of the lung could become a clinically useful tool in the near future.

Yuh-Chin T. Huang, MD, MHS, FCCP

Steering Committee Member

 

 

Thoracic Oncology

Immune-mediated pneumonitis and PD-1 inhibition

Inhibitors of the programmed cell death 1 receptor (PD-1) have shown significant promise in the treatment of advanced stage malignancy. With the recent expansion of indications for use of these agents, the number of patients treated will continue to grow. Clinicians must be aware of their potential for serious adverse side effects, including dermatitis, colitis, and potentially life-threatening pneumonitis.

The development of pneumonitis secondary to PD-1 inhibitions is reported to occur in 2% to 5% of patients and can present at any time during therapy, with 1% of patients developing grade 3 or higher pneumonitis.^1,2 The most common symptoms are dyspnea and cough, though one-third of patients are asymptomatic at presentation.² Radiographic and pathologic features vary greatly and include organizing pneumonia, interstitial pneumonitis, hypersensitivity pneumonitis, or diffuse alveolar damage.³ While pneumonitis due to PD-1 inhibition is reportedly uncommon, the increasing number of patients expected to receive these medications will predictably result in increasing overall frequency of pneumonitis cases. In addition, the lack of large prospective randomized trials and reliance on radiographic rather than pathologic data in diagnosing immune-mediated pneumonitis gives one pause. Given the variability of presentation, lack of routine pathologic data, and increasing use of dual agents (eg, PD-1 and CTLA-4), chest physicians and medical oncologists should have a high index of suspicion yet practice equipoise in patients receiving immunotherapy who develop unexplained pulmonary symptoms or infiltrates. More research is needed to help improve the multidisciplinary diagnosis and treatment of this potentially serious complication.

David Maurice Chambers, MD
Fellow-in-Training Member

Jason Atticus Akulian, MD, MPH
Steering Committee Member

References

1. Nishino M, et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncology. 2016;2(12):1607.

2. Naidoo J, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35(7):709.

3. Nishino M, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res. 2016;22(24):6051.

Pulmonary Vascular Disease

Pulmonary Arterial Hypertension Associated With SLE

While pulmonary arterial hypertension (PAH) commonly complicates scleroderma (SSc), it is a rare complication of other connective tissue diseases (CTD), such as systemic lupus erythematosus (SLE). In the few prospective studies that utilize right-sided heart catheterization (RHC), the estimated prevalence of PAH in SLE is about 4%. However, since the prevalence of SLE is 10 to 15 times greater than SSc in the United States, the true prevalence of SLE-PAH may be higher than previously thought, and, thus, clinically relevant. Despite this, little is known about SLE-PAH.

A recent retrospective study from the French Pulmonary Hypertension Registry has added significantly to our understanding of this complication of SLE. Hachulla and colleagues studied 51 patients with RHC-proven SLE-PAH compared with 101 SLE control subjects without PAH. While the authors did not find any relevant differences in the demographics between groups, they did find a significantly higher prevalence of SSA and SSB antibodies in SLE-PAH. Interestingly, the presence of anti-U1 RNP antibody appeared to be less common in SLE-PAH patients; this lack of association is in contrast to prior studies in mixed CTD patients with anti-U1 RNP antibodies in which the prevalence of PAH can be as high as 60%. Further, none of the SLE-PAH patients demonstrated an acute response to vasodilator challenge during RHC, emphasizing that this maneuver does not need to be performed in SLE patients at risk of PAH. Trends toward improved survival in SLE-PAH patients treated with hydroxychloroquine are preliminary and hypothesis-generating but require confirmation in larger clinical studies.

Stephen Mathai, MD, FCCP
Chair

Leena Palwar, MD
Fellow-in-Training Member

References

Hachulla E, Jais X, Cinquetti G, et al. Pulmonary arterial hypertension associated with SLE: Results from the French pulmonary hypertension registry. Chest. 2017 Aug 26. pii: S0012-3692(17)31430-7. doi: 10.1016/j.chest.2017.08.014. [Epub ahead of print]

Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010;138:1383-1394.

Shirai Y, Yasuoka H, Okano Y, Takeuchi T, Satoh T, Kuwana M. Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a singlecentre cohort. Rheumatology. 2012;51:1846-1854.

Hao YJ, Jiang X, Zhou W, et al. Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients. Eur Respir J. 2014;44: 963-972.

Huang C, Li M, Liu Y, et al. Baseline characteristics and risk factors of pulmonary arterial hypertension in systemic lupus erythematosus patients. Medicine. 2016;95:e2761.

Pérez-Peñate GM, Rúa-Figueroa I, Juliá- Serdá G, et al. Pulmonary arterial hypertension in systemic lupus erythematosus: prevalence and predictors. J Rheumatol. 2016;43:323-329.

Alpert MA, Goldberg SH, Sindem BH, et al. Cardiovascular manifestations of mixed connective tissue disease in adults. Circulation. 1983;63:1182-1193.

Interventional Chest/Diagnostic Procedures

Cryobiopsy for ILD: Careful stewardship needed

Interest in transbronchial cryobiopsy has accelerated rapidly in recent years. This procedure is performed by advancing a cryoprobe into the peripheral lung via flexible bronchoscopy, where lung tissue freezes and adheres to the probe and is subsequently extracted as a cryobiopsy. The number of cryobiopsy-related publications has increased exponentially since it was described in 2009 (Babiak A, et al. Respiration. 2009;78[2]:203). This interest stems from reports of high diagnostic yields in patients with interstitial lung disease (ILD) while maintaining complication rates similar to that of conventional bronchoscopic biopsy.

Traditional bronchoscopic biopsies are notoriously insensitive; a specific diagnosis can be established in fewer than a third of cases (Sheth JS, et al. Chest. 2017;151[2]:389). As such, surgical lung biopsy continues to be recommended but is associated with significant mortality (2%) and morbidity (30%) in patients with ILD (Hutchinson JP, et al. ARJCCM. 2016;193[10]:1161). Cryobiopsy, which appears to rival surgical lung biopsy in terms of ability to contribute to a specific diagnosis, is, therefore, a highly promising alternative (Tomassetti S, et al. AJRCCM. 2016;193[7]:745).

As cryobiopsy is increasingly adopted around the world, however, troubling reports of serious complications have surfaced. Most notable is the recently reported experience of the initial 25 cases performed at the University of Pennsylvania, in which almost one in four patients suffered serious complications (DiBardino DM, et al. Ann Am Thorac Soc. 2017;14[6]:851). The authors pointed to lack of a predefined procedural protocol, as well as several choices relating to the specific technique used, including inconsistent use of fluoroscopy, lack of prophylactic bronchial blocker placement, and predominant use of laryngeal mask airways as potential contributing factors. Indeed, many variations of the basic cryobiopsy procedure have been described (Lentz RJ, et al. J Thoracic Dis. 2017;9[7]:2186), with no formal guidance or training available to inform advanced bronchoscopists interested in this procedure.

It is incumbent on the interventional pulmonology and ILD specialist communities to be responsible stewards of this promising procedure. Implementation of three parallel efforts to standardize and rigorously study this procedure should be considered as soon as possible: creation of expert consensus guidelines establishing best-practices for safe and effective biopsy technique; a training requirement before independent performance of the procedure; and creation of an international cryobiopsy registry to facilitate higher-quality research into optimal technique and outcomes. We owe this to our patients.

Robert J. Lentz, MD
NetWork Member

Fabien Maldonado, MD, FCCP
NetWork Member

Pediatric Chest Medicine

Chronic cough in children: New guidelines

A chronic cough is a common complaint among children whose parents seek medical evaluation. Chronic wet cough can indicate an underlying illness; therefore, an early diagnosis can lead to prevention of complications of the disease and improvement in quality of life.

CHEST is a leading resource in evidence and consensus-based guidelines on important topics affecting children. The most recent guidelines entitled Management of Children with Chronic Wet Cough and Protracted Bacterial Bronchitis (Chest. 2017;151(4):884-890) and Use of Management Pathways or Algorithms in Children with Chronic Cough (Chest. 2017;151(4):875-873) are updates from the 2006 CHEST guidelines on chronic cough in children.

The present updates utilized the CHEST methodological guidelines with chronic wet or productive cough and Grading of Recommendations Assessment, Development, and Evaluation framework and also performed a systematic review addressing key questions concerning the management of childhood disease for children 14 years and younger.

Guidance provided by the expert panel focused on recommendations to answer six key questions concerning the management of children 14 years and younger with a chronic wet cough unrelated to established chronic lung disease. The recommendations are:

1. Chronic cough is defined as the presence of a cough 4 weeks or longer in duration.

2. Assessment of the effect of the cough on the child and the family be undertaken as part of clinical consultation.

3. Evaluation of a chronic cough should be done with a systematic approach with pediatric-specific cough management protocols or algorithms.

4. Chest radiograph and, when age appropriate, spirometry with bronchodilator be undertaken as evaluation; tests for pertussis infection only to be performed if clinically suspected.

5. Chronic wet cough with no specific clinical features should receive antibiotics for 2 weeks targeted for common respiratory bacteria (Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis).

6. When cough persists despite 2 weeks of appropriate antibiotics, it is recommended to continue for an additional 2 weeks.

7. Additional tests (eg skin prick test, Mantoux, bronchoscopy, chest CT scan) should be individualized in accordance with the clinical setting and child’s clinical symptoms and signs.

The panel recognizes the need for prospective studies to assess current algorithms outcomes of children with chronic cough. Both articles can be found on the guidelines section of the CHEST site.

John Bishara, DO
Fellow-in-Training Member

Pulmonary Physiology, Function, and Rehabilitation

Functional imaging of the lung

Quantifying heterogeneity of ventilation and gas exchange in lung diseases remains a clinical challenge. Conventional pulmonary function test is insensitive to regional changes. The multiple inert gas elimination technique can quantify ventilation-perfusion distribution, but it requires invasive instrumentation (eg, pulmonary artery catheterization) and is not practical for clinical use. Computed tomography (CT) scans delineate spatial changes in lung structures but do not directly measure changes in ventilation and gas exchange. With its radiation, it is difficult to apply CT scanning repeatedly in patients. More recently, MR imaging techniques have been developed to directly “visualize” and quantify regional lung function (Kruger SJ, et al. J Magn Reson Imaging. 2016;43(2):295; Roos JE, et al. Magn Reson Imaging Clin N Am. 2015;23(2):217). These techniques employ inhalation of gases, such as oxygen, perfluorinated gases, and hyperpolarized ³He and ¹²⁹Xe. Hyperpolarized ³He has been studied the most; however, the dwindling supply of ³He gas and its rising cost have prevented its further development. ¹²⁹Xe has abundant supply and has emerged to be the inert gas of choice for MR imaging. Hyperpolarized ¹²⁹Xe can measure ventilation, like hyperpolarized ³He. In addition, Xe diffuses into alveolar barrier (interstitium and plasma) and red blood cells, where it exhibits distinct resonant frequency shifts that can be captured by MR. Therefore, in one test, information on pulmonary ventilation and gas transfer can be obtained. To date, the results from MR imaging studies have provided new insights into the pathophysiology of obstructive and restrictive lung diseases. With continuous development, MR imaging of the lung could become a clinically useful tool in the near future.

Yuh-Chin T. Huang, MD, MHS, FCCP

Steering Committee Member

 

 

Thoracic Oncology

Immune-mediated pneumonitis and PD-1 inhibition

Inhibitors of the programmed cell death 1 receptor (PD-1) have shown significant promise in the treatment of advanced stage malignancy. With the recent expansion of indications for use of these agents, the number of patients treated will continue to grow. Clinicians must be aware of their potential for serious adverse side effects, including dermatitis, colitis, and potentially life-threatening pneumonitis.

The development of pneumonitis secondary to PD-1 inhibitions is reported to occur in 2% to 5% of patients and can present at any time during therapy, with 1% of patients developing grade 3 or higher pneumonitis.^1,2 The most common symptoms are dyspnea and cough, though one-third of patients are asymptomatic at presentation.² Radiographic and pathologic features vary greatly and include organizing pneumonia, interstitial pneumonitis, hypersensitivity pneumonitis, or diffuse alveolar damage.³ While pneumonitis due to PD-1 inhibition is reportedly uncommon, the increasing number of patients expected to receive these medications will predictably result in increasing overall frequency of pneumonitis cases. In addition, the lack of large prospective randomized trials and reliance on radiographic rather than pathologic data in diagnosing immune-mediated pneumonitis gives one pause. Given the variability of presentation, lack of routine pathologic data, and increasing use of dual agents (eg, PD-1 and CTLA-4), chest physicians and medical oncologists should have a high index of suspicion yet practice equipoise in patients receiving immunotherapy who develop unexplained pulmonary symptoms or infiltrates. More research is needed to help improve the multidisciplinary diagnosis and treatment of this potentially serious complication.

David Maurice Chambers, MD
Fellow-in-Training Member

Jason Atticus Akulian, MD, MPH
Steering Committee Member

References

1. Nishino M, et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncology. 2016;2(12):1607.

2. Naidoo J, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35(7):709.

3. Nishino M, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res. 2016;22(24):6051.

Pulmonary Vascular Disease

Pulmonary Arterial Hypertension Associated With SLE

While pulmonary arterial hypertension (PAH) commonly complicates scleroderma (SSc), it is a rare complication of other connective tissue diseases (CTD), such as systemic lupus erythematosus (SLE). In the few prospective studies that utilize right-sided heart catheterization (RHC), the estimated prevalence of PAH in SLE is about 4%. However, since the prevalence of SLE is 10 to 15 times greater than SSc in the United States, the true prevalence of SLE-PAH may be higher than previously thought, and, thus, clinically relevant. Despite this, little is known about SLE-PAH.

A recent retrospective study from the French Pulmonary Hypertension Registry has added significantly to our understanding of this complication of SLE. Hachulla and colleagues studied 51 patients with RHC-proven SLE-PAH compared with 101 SLE control subjects without PAH. While the authors did not find any relevant differences in the demographics between groups, they did find a significantly higher prevalence of SSA and SSB antibodies in SLE-PAH. Interestingly, the presence of anti-U1 RNP antibody appeared to be less common in SLE-PAH patients; this lack of association is in contrast to prior studies in mixed CTD patients with anti-U1 RNP antibodies in which the prevalence of PAH can be as high as 60%. Further, none of the SLE-PAH patients demonstrated an acute response to vasodilator challenge during RHC, emphasizing that this maneuver does not need to be performed in SLE patients at risk of PAH. Trends toward improved survival in SLE-PAH patients treated with hydroxychloroquine are preliminary and hypothesis-generating but require confirmation in larger clinical studies.

Stephen Mathai, MD, FCCP
Chair

Leena Palwar, MD
Fellow-in-Training Member

References

Hachulla E, Jais X, Cinquetti G, et al. Pulmonary arterial hypertension associated with SLE: Results from the French pulmonary hypertension registry. Chest. 2017 Aug 26. pii: S0012-3692(17)31430-7. doi: 10.1016/j.chest.2017.08.014. [Epub ahead of print]

Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010;138:1383-1394.

Shirai Y, Yasuoka H, Okano Y, Takeuchi T, Satoh T, Kuwana M. Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a singlecentre cohort. Rheumatology. 2012;51:1846-1854.

Hao YJ, Jiang X, Zhou W, et al. Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients. Eur Respir J. 2014;44: 963-972.

Huang C, Li M, Liu Y, et al. Baseline characteristics and risk factors of pulmonary arterial hypertension in systemic lupus erythematosus patients. Medicine. 2016;95:e2761.

Pérez-Peñate GM, Rúa-Figueroa I, Juliá- Serdá G, et al. Pulmonary arterial hypertension in systemic lupus erythematosus: prevalence and predictors. J Rheumatol. 2016;43:323-329.

Alpert MA, Goldberg SH, Sindem BH, et al. Cardiovascular manifestations of mixed connective tissue disease in adults. Circulation. 1983;63:1182-1193.

Interventional Chest/Diagnostic Procedures

Cryobiopsy for ILD: Careful stewardship needed

Interest in transbronchial cryobiopsy has accelerated rapidly in recent years. This procedure is performed by advancing a cryoprobe into the peripheral lung via flexible bronchoscopy, where lung tissue freezes and adheres to the probe and is subsequently extracted as a cryobiopsy. The number of cryobiopsy-related publications has increased exponentially since it was described in 2009 (Babiak A, et al. Respiration. 2009;78[2]:203). This interest stems from reports of high diagnostic yields in patients with interstitial lung disease (ILD) while maintaining complication rates similar to that of conventional bronchoscopic biopsy.

Traditional bronchoscopic biopsies are notoriously insensitive; a specific diagnosis can be established in fewer than a third of cases (Sheth JS, et al. Chest. 2017;151[2]:389). As such, surgical lung biopsy continues to be recommended but is associated with significant mortality (2%) and morbidity (30%) in patients with ILD (Hutchinson JP, et al. ARJCCM. 2016;193[10]:1161). Cryobiopsy, which appears to rival surgical lung biopsy in terms of ability to contribute to a specific diagnosis, is, therefore, a highly promising alternative (Tomassetti S, et al. AJRCCM. 2016;193[7]:745).

As cryobiopsy is increasingly adopted around the world, however, troubling reports of serious complications have surfaced. Most notable is the recently reported experience of the initial 25 cases performed at the University of Pennsylvania, in which almost one in four patients suffered serious complications (DiBardino DM, et al. Ann Am Thorac Soc. 2017;14[6]:851). The authors pointed to lack of a predefined procedural protocol, as well as several choices relating to the specific technique used, including inconsistent use of fluoroscopy, lack of prophylactic bronchial blocker placement, and predominant use of laryngeal mask airways as potential contributing factors. Indeed, many variations of the basic cryobiopsy procedure have been described (Lentz RJ, et al. J Thoracic Dis. 2017;9[7]:2186), with no formal guidance or training available to inform advanced bronchoscopists interested in this procedure.

It is incumbent on the interventional pulmonology and ILD specialist communities to be responsible stewards of this promising procedure. Implementation of three parallel efforts to standardize and rigorously study this procedure should be considered as soon as possible: creation of expert consensus guidelines establishing best-practices for safe and effective biopsy technique; a training requirement before independent performance of the procedure; and creation of an international cryobiopsy registry to facilitate higher-quality research into optimal technique and outcomes. We owe this to our patients.

Robert J. Lentz, MD
NetWork Member

Fabien Maldonado, MD, FCCP
NetWork Member

Pediatric Chest Medicine

Chronic cough in children: New guidelines

A chronic cough is a common complaint among children whose parents seek medical evaluation. Chronic wet cough can indicate an underlying illness; therefore, an early diagnosis can lead to prevention of complications of the disease and improvement in quality of life.

CHEST is a leading resource in evidence and consensus-based guidelines on important topics affecting children. The most recent guidelines entitled Management of Children with Chronic Wet Cough and Protracted Bacterial Bronchitis (Chest. 2017;151(4):884-890) and Use of Management Pathways or Algorithms in Children with Chronic Cough (Chest. 2017;151(4):875-873) are updates from the 2006 CHEST guidelines on chronic cough in children.

The present updates utilized the CHEST methodological guidelines with chronic wet or productive cough and Grading of Recommendations Assessment, Development, and Evaluation framework and also performed a systematic review addressing key questions concerning the management of childhood disease for children 14 years and younger.

Guidance provided by the expert panel focused on recommendations to answer six key questions concerning the management of children 14 years and younger with a chronic wet cough unrelated to established chronic lung disease. The recommendations are:

1. Chronic cough is defined as the presence of a cough 4 weeks or longer in duration.

2. Assessment of the effect of the cough on the child and the family be undertaken as part of clinical consultation.

3. Evaluation of a chronic cough should be done with a systematic approach with pediatric-specific cough management protocols or algorithms.

4. Chest radiograph and, when age appropriate, spirometry with bronchodilator be undertaken as evaluation; tests for pertussis infection only to be performed if clinically suspected.

5. Chronic wet cough with no specific clinical features should receive antibiotics for 2 weeks targeted for common respiratory bacteria (Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis).

6. When cough persists despite 2 weeks of appropriate antibiotics, it is recommended to continue for an additional 2 weeks.

7. Additional tests (eg skin prick test, Mantoux, bronchoscopy, chest CT scan) should be individualized in accordance with the clinical setting and child’s clinical symptoms and signs.

The panel recognizes the need for prospective studies to assess current algorithms outcomes of children with chronic cough. Both articles can be found on the guidelines section of the CHEST site.

John Bishara, DO
Fellow-in-Training Member

Pulmonary Physiology, Function, and Rehabilitation

Functional imaging of the lung

Quantifying heterogeneity of ventilation and gas exchange in lung diseases remains a clinical challenge. Conventional pulmonary function test is insensitive to regional changes. The multiple inert gas elimination technique can quantify ventilation-perfusion distribution, but it requires invasive instrumentation (eg, pulmonary artery catheterization) and is not practical for clinical use. Computed tomography (CT) scans delineate spatial changes in lung structures but do not directly measure changes in ventilation and gas exchange. With its radiation, it is difficult to apply CT scanning repeatedly in patients. More recently, MR imaging techniques have been developed to directly “visualize” and quantify regional lung function (Kruger SJ, et al. J Magn Reson Imaging. 2016;43(2):295; Roos JE, et al. Magn Reson Imaging Clin N Am. 2015;23(2):217). These techniques employ inhalation of gases, such as oxygen, perfluorinated gases, and hyperpolarized ³He and ¹²⁹Xe. Hyperpolarized ³He has been studied the most; however, the dwindling supply of ³He gas and its rising cost have prevented its further development. ¹²⁹Xe has abundant supply and has emerged to be the inert gas of choice for MR imaging. Hyperpolarized ¹²⁹Xe can measure ventilation, like hyperpolarized ³He. In addition, Xe diffuses into alveolar barrier (interstitium and plasma) and red blood cells, where it exhibits distinct resonant frequency shifts that can be captured by MR. Therefore, in one test, information on pulmonary ventilation and gas transfer can be obtained. To date, the results from MR imaging studies have provided new insights into the pathophysiology of obstructive and restrictive lung diseases. With continuous development, MR imaging of the lung could become a clinically useful tool in the near future.

Yuh-Chin T. Huang, MD, MHS, FCCP

Steering Committee Member

 

 

Thoracic Oncology

Immune-mediated pneumonitis and PD-1 inhibition

Inhibitors of the programmed cell death 1 receptor (PD-1) have shown significant promise in the treatment of advanced stage malignancy. With the recent expansion of indications for use of these agents, the number of patients treated will continue to grow. Clinicians must be aware of their potential for serious adverse side effects, including dermatitis, colitis, and potentially life-threatening pneumonitis.

The development of pneumonitis secondary to PD-1 inhibitions is reported to occur in 2% to 5% of patients and can present at any time during therapy, with 1% of patients developing grade 3 or higher pneumonitis.^1,2 The most common symptoms are dyspnea and cough, though one-third of patients are asymptomatic at presentation.² Radiographic and pathologic features vary greatly and include organizing pneumonia, interstitial pneumonitis, hypersensitivity pneumonitis, or diffuse alveolar damage.³ While pneumonitis due to PD-1 inhibition is reportedly uncommon, the increasing number of patients expected to receive these medications will predictably result in increasing overall frequency of pneumonitis cases. In addition, the lack of large prospective randomized trials and reliance on radiographic rather than pathologic data in diagnosing immune-mediated pneumonitis gives one pause. Given the variability of presentation, lack of routine pathologic data, and increasing use of dual agents (eg, PD-1 and CTLA-4), chest physicians and medical oncologists should have a high index of suspicion yet practice equipoise in patients receiving immunotherapy who develop unexplained pulmonary symptoms or infiltrates. More research is needed to help improve the multidisciplinary diagnosis and treatment of this potentially serious complication.

David Maurice Chambers, MD
Fellow-in-Training Member

Jason Atticus Akulian, MD, MPH
Steering Committee Member

References

1. Nishino M, et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncology. 2016;2(12):1607.

2. Naidoo J, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35(7):709.

3. Nishino M, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res. 2016;22(24):6051.

Pulmonary Vascular Disease

Pulmonary Arterial Hypertension Associated With SLE

While pulmonary arterial hypertension (PAH) commonly complicates scleroderma (SSc), it is a rare complication of other connective tissue diseases (CTD), such as systemic lupus erythematosus (SLE). In the few prospective studies that utilize right-sided heart catheterization (RHC), the estimated prevalence of PAH in SLE is about 4%. However, since the prevalence of SLE is 10 to 15 times greater than SSc in the United States, the true prevalence of SLE-PAH may be higher than previously thought, and, thus, clinically relevant. Despite this, little is known about SLE-PAH.

A recent retrospective study from the French Pulmonary Hypertension Registry has added significantly to our understanding of this complication of SLE. Hachulla and colleagues studied 51 patients with RHC-proven SLE-PAH compared with 101 SLE control subjects without PAH. While the authors did not find any relevant differences in the demographics between groups, they did find a significantly higher prevalence of SSA and SSB antibodies in SLE-PAH. Interestingly, the presence of anti-U1 RNP antibody appeared to be less common in SLE-PAH patients; this lack of association is in contrast to prior studies in mixed CTD patients with anti-U1 RNP antibodies in which the prevalence of PAH can be as high as 60%. Further, none of the SLE-PAH patients demonstrated an acute response to vasodilator challenge during RHC, emphasizing that this maneuver does not need to be performed in SLE patients at risk of PAH. Trends toward improved survival in SLE-PAH patients treated with hydroxychloroquine are preliminary and hypothesis-generating but require confirmation in larger clinical studies.

Stephen Mathai, MD, FCCP
Chair

Leena Palwar, MD
Fellow-in-Training Member

References

Hachulla E, Jais X, Cinquetti G, et al. Pulmonary arterial hypertension associated with SLE: Results from the French pulmonary hypertension registry. Chest. 2017 Aug 26. pii: S0012-3692(17)31430-7. doi: 10.1016/j.chest.2017.08.014. [Epub ahead of print]

Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010;138:1383-1394.

Shirai Y, Yasuoka H, Okano Y, Takeuchi T, Satoh T, Kuwana M. Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a singlecentre cohort. Rheumatology. 2012;51:1846-1854.

Hao YJ, Jiang X, Zhou W, et al. Connective tissue disease-associated pulmonary arterial hypertension in Chinese patients. Eur Respir J. 2014;44: 963-972.

Huang C, Li M, Liu Y, et al. Baseline characteristics and risk factors of pulmonary arterial hypertension in systemic lupus erythematosus patients. Medicine. 2016;95:e2761.

Pérez-Peñate GM, Rúa-Figueroa I, Juliá- Serdá G, et al. Pulmonary arterial hypertension in systemic lupus erythematosus: prevalence and predictors. J Rheumatol. 2016;43:323-329.

Alpert MA, Goldberg SH, Sindem BH, et al. Cardiovascular manifestations of mixed connective tissue disease in adults. Circulation. 1983;63:1182-1193.

CHEST 2017 offers several contests and opportunities to win great prizes! Are you ready to take home the prize?
 

CHEST Events App Game: Click Game

Rules of participation

Are you a VITweep?

Get active on Twitter, and share your latest highlights for #CHEST2017! Sitting in on an interesting session? Having a great time visiting the posters? Let us know! The most active tweeters for the day will receive a special prize!

Share your selfies!

See a selfie spot and take advantage of it! We know there’s more to your trip than lectures and keynote speakers, and we want to see it!

Throughout the convention center, you’ll find many designated areas to snap and share photos of yourself and colleagues! Be sure to find them all and share your images on Twitter or Instagram using our #CHEST2017 hashtag. We’ll choose our favorite photo of the day and reshare your pic­ture with our social media followers. Don’t miss your chance to be featured!
 

Don’t miss out on CHEST Bingo

Take advantage of one of the many opportunities in the Exhibit Hall during CHEST. Play CHEST Bingo daily, starting Monday, October 30, through Wednesday, November 1, for a chance to win a prize!

How to play:

Find your bingo card in the program guide that you will receive during registration. Get each bingo letter to spell out C-H-E-S-T as you visit each of the five sponsors’ booths. You will then have a chance to win a $75 gift certificate to the CHEST bookstore. There will be a winner drawn every night!

Win an iPad®!

This year, attendees will have the opportunity to win a refurbished iPad for playing one of our Simulation Center’s arcade style GAMEs (Games Augmenting Medical Education). Last year, we gave away 15 refurbished iPad 2s; this year, we hope to give away 30 refurbished iPad 2s!

iPads will be awarded for the following:

• One each day for the fastest time on Aspirated!
• One each day for whoever has played the most games and Virtual Patient Tours (VPTs).
• Several for playing the games Peer Pressure and Nodal Nemesis.

Please refer to the program schedule in the CHEST Events app for dates and times of the GAMEs and VPTs.

CHEST 2017 offers several contests and opportunities to win great prizes! Are you ready to take home the prize?
 

CHEST Events App Game: Click Game

Rules of participation

Are you a VITweep?

Get active on Twitter, and share your latest highlights for #CHEST2017! Sitting in on an interesting session? Having a great time visiting the posters? Let us know! The most active tweeters for the day will receive a special prize!

Share your selfies!

See a selfie spot and take advantage of it! We know there’s more to your trip than lectures and keynote speakers, and we want to see it!

Throughout the convention center, you’ll find many designated areas to snap and share photos of yourself and colleagues! Be sure to find them all and share your images on Twitter or Instagram using our #CHEST2017 hashtag. We’ll choose our favorite photo of the day and reshare your pic­ture with our social media followers. Don’t miss your chance to be featured!
 

Don’t miss out on CHEST Bingo

Take advantage of one of the many opportunities in the Exhibit Hall during CHEST. Play CHEST Bingo daily, starting Monday, October 30, through Wednesday, November 1, for a chance to win a prize!

How to play:

Find your bingo card in the program guide that you will receive during registration. Get each bingo letter to spell out C-H-E-S-T as you visit each of the five sponsors’ booths. You will then have a chance to win a $75 gift certificate to the CHEST bookstore. There will be a winner drawn every night!

Win an iPad®!

This year, attendees will have the opportunity to win a refurbished iPad for playing one of our Simulation Center’s arcade style GAMEs (Games Augmenting Medical Education). Last year, we gave away 15 refurbished iPad 2s; this year, we hope to give away 30 refurbished iPad 2s!

iPads will be awarded for the following:

• One each day for the fastest time on Aspirated!
• One each day for whoever has played the most games and Virtual Patient Tours (VPTs).
• Several for playing the games Peer Pressure and Nodal Nemesis.

Please refer to the program schedule in the CHEST Events app for dates and times of the GAMEs and VPTs.

CHEST 2017 offers several contests and opportunities to win great prizes! Are you ready to take home the prize?
 

CHEST Events App Game: Click Game

Rules of participation

Are you a VITweep?

Get active on Twitter, and share your latest highlights for #CHEST2017! Sitting in on an interesting session? Having a great time visiting the posters? Let us know! The most active tweeters for the day will receive a special prize!

Share your selfies!

See a selfie spot and take advantage of it! We know there’s more to your trip than lectures and keynote speakers, and we want to see it!

Throughout the convention center, you’ll find many designated areas to snap and share photos of yourself and colleagues! Be sure to find them all and share your images on Twitter or Instagram using our #CHEST2017 hashtag. We’ll choose our favorite photo of the day and reshare your pic­ture with our social media followers. Don’t miss your chance to be featured!
 

Don’t miss out on CHEST Bingo

Take advantage of one of the many opportunities in the Exhibit Hall during CHEST. Play CHEST Bingo daily, starting Monday, October 30, through Wednesday, November 1, for a chance to win a prize!

How to play:

Find your bingo card in the program guide that you will receive during registration. Get each bingo letter to spell out C-H-E-S-T as you visit each of the five sponsors’ booths. You will then have a chance to win a $75 gift certificate to the CHEST bookstore. There will be a winner drawn every night!

Win an iPad®!

This year, attendees will have the opportunity to win a refurbished iPad for playing one of our Simulation Center’s arcade style GAMEs (Games Augmenting Medical Education). Last year, we gave away 15 refurbished iPad 2s; this year, we hope to give away 30 refurbished iPad 2s!

iPads will be awarded for the following:

• One each day for the fastest time on Aspirated!
• One each day for whoever has played the most games and Virtual Patient Tours (VPTs).
• Several for playing the games Peer Pressure and Nodal Nemesis.

Please refer to the program schedule in the CHEST Events app for dates and times of the GAMEs and VPTs.

John Studdard, MD, FCCP, has been a member of the American College of Chest Physicians for 36 years, and, this November, he will be inaugurated as CHEST President. This will not be Dr. Studdard’s first time in a presidential role for CHEST, as he served as CHEST Foundation President in 2013 and 2014. Currently, Dr. Studdard serves as a pulmonologist at Jackson Pulmonary in Jackson, Mississippi. Being a physician and being as heavily involved with an organization as Dr. Studdard is takes a lot of prioritizing, hard work, and dedication. Get to know CHEST’s new President through this interview.

Born and raised in Mississippi, Dr. Studdard says there were four factors that inspired him to become a physician:

1. I have always loved people and working with them, and I always admired the respect that physicians received in my community.

What are some of the biggest challenges you have encountered throughout your career?

Private practice makes you gain more independence and autonomy; you have to become more agile, more efficient, and you have awfully big workloads. However, you give up the academic stimulation of being in an academic center. It is a tough discipline in the private practice of medicine to try to stay up to date. Whether going to the CHEST Annual Meeting, reading our journal CHEST, or looking at CHEST education online products, those of us in the clinical practice of pulmonary, critical care, and sleep medicine are more dependent than any group on what our clinical educators write and teach.
 

How do/did you balance work and your personal life?

We are busy in practice, particularly when taking on volunteer opportunities, and that time comes out of something: time with family, hobbies, it has to come from somewhere. But it is not unique to those of us in medicine. My daughter is a 33-year-old mother to a 20-month-old beautiful granddaughter of ours and is pregnant with another child, and she and her husband both work full time. Our son and his wife also both work and must find ways to balance work/life issues. So work-life balance, particularly in today’s world, is more difficult than ever for everyone. I am blessed that my wife is the daughter of a general surgeon, and she understood a little bit about stressors in a physician’s life – sometimes she seems to understand more than others—she is a unique person. Work-life balance is all about priorities – our priority was our family. We spent a ton of time with our children, great vacations, rarely missed a program or ballgame (there were lots of them), and frequently that involved going to work early in the morning, coming home early in the evening, and going back to the hospital to finish up late at night. A lot of being a good parent is being lucky. We either did a lot of things right, or were lucky, or a combination of both, because I think our kids turned out pretty darn well.
 

What has been your favorite project throughout your involvement with CHEST?

Early in my days as a member of CHEST, a mentor of mine from training at the Mayo Clinic, Dr. Doug Gracey, gave me the opportunity to join the CHEST Government Relations Committee, which he chaired. After a few years, I was given the opportunity to serve as its Chair. We became heavily involved in the tobacco wars, as some people called them. Our Attorney General in Mississippi at the time, Mike Moore, and a plaintiff’s attorney in Mississippi, Dick Scruggs, whom I knew from some work I had done from the defense side of asbestos litigation, took a lead role in the Attorney General’s Master Settlement - a group of attorney generals suing the tobacco industry (basically, state’s Medicaid was suing the tobacco industry for reimbursement of funds). It was a completely different approach. The tobacco industry turned its nose up at it at first – they did not think it had a chance to fly, but it did. CHEST got involved early on, and then a big a group of people, including Tobacco Free Kids, the American Cancer Society, and many others in the public health space, got involved. CHEST represented the public health community during part of the negotiations that led to the Attorney General’s Master Settlement. We should be very proud of the role CHEST played in this critical public health effort. If I can look back at my time spent in CHEST leadership, and see it as fondly as I do when I look back at my time just being a part of our CHEST Foundation, I will feel incredibly fulfilled.
 

What made you want to be President of CHEST?

I believe it is always important to give back to the people who gave you something. CHEST has given me a ton over the last 36 years, so giving back to CHEST is easy.
 

What are you looking forward to as President of CHEST?

On a personal level, I am looking forward to what we are doing right now, meeting new people, and learning from young people.

Because of my background and upbringing, I have a passion for diversity and inclusion; I think we need to continue to talk about, learn about, care about, be open about, and be transparent about diversity of thought, inclusion, and care disparity. The word “diversity” means something different to every person, and, for that, we have to have respect.

As Dr. Studdard prepares to take on his new role in CHEST leadership this October, he is optimistic about what the future will bring and about the things that he will learn. He considers himself incredibly lucky to be in the position that he is in, and he values each relationship he has made during his involvement with CHEST. He is looking forward to all that is in store during his time as President. He left us with a quote from Wyatt Cooper:

“The only immortality we can be sure of is that part of ourselves we invest in others—the contribution we make to the totality of man, the knowledge we have shared, the truths we have found, the causes we have served, the lessons we have lived.”

John Studdard, MD, FCCP, has been a member of the American College of Chest Physicians for 36 years, and, this November, he will be inaugurated as CHEST President. This will not be Dr. Studdard’s first time in a presidential role for CHEST, as he served as CHEST Foundation President in 2013 and 2014. Currently, Dr. Studdard serves as a pulmonologist at Jackson Pulmonary in Jackson, Mississippi. Being a physician and being as heavily involved with an organization as Dr. Studdard is takes a lot of prioritizing, hard work, and dedication. Get to know CHEST’s new President through this interview.

Born and raised in Mississippi, Dr. Studdard says there were four factors that inspired him to become a physician:

1. I have always loved people and working with them, and I always admired the respect that physicians received in my community.

What are some of the biggest challenges you have encountered throughout your career?

Private practice makes you gain more independence and autonomy; you have to become more agile, more efficient, and you have awfully big workloads. However, you give up the academic stimulation of being in an academic center. It is a tough discipline in the private practice of medicine to try to stay up to date. Whether going to the CHEST Annual Meeting, reading our journal CHEST, or looking at CHEST education online products, those of us in the clinical practice of pulmonary, critical care, and sleep medicine are more dependent than any group on what our clinical educators write and teach.
 

How do/did you balance work and your personal life?

We are busy in practice, particularly when taking on volunteer opportunities, and that time comes out of something: time with family, hobbies, it has to come from somewhere. But it is not unique to those of us in medicine. My daughter is a 33-year-old mother to a 20-month-old beautiful granddaughter of ours and is pregnant with another child, and she and her husband both work full time. Our son and his wife also both work and must find ways to balance work/life issues. So work-life balance, particularly in today’s world, is more difficult than ever for everyone. I am blessed that my wife is the daughter of a general surgeon, and she understood a little bit about stressors in a physician’s life – sometimes she seems to understand more than others—she is a unique person. Work-life balance is all about priorities – our priority was our family. We spent a ton of time with our children, great vacations, rarely missed a program or ballgame (there were lots of them), and frequently that involved going to work early in the morning, coming home early in the evening, and going back to the hospital to finish up late at night. A lot of being a good parent is being lucky. We either did a lot of things right, or were lucky, or a combination of both, because I think our kids turned out pretty darn well.
 

What has been your favorite project throughout your involvement with CHEST?

Early in my days as a member of CHEST, a mentor of mine from training at the Mayo Clinic, Dr. Doug Gracey, gave me the opportunity to join the CHEST Government Relations Committee, which he chaired. After a few years, I was given the opportunity to serve as its Chair. We became heavily involved in the tobacco wars, as some people called them. Our Attorney General in Mississippi at the time, Mike Moore, and a plaintiff’s attorney in Mississippi, Dick Scruggs, whom I knew from some work I had done from the defense side of asbestos litigation, took a lead role in the Attorney General’s Master Settlement - a group of attorney generals suing the tobacco industry (basically, state’s Medicaid was suing the tobacco industry for reimbursement of funds). It was a completely different approach. The tobacco industry turned its nose up at it at first – they did not think it had a chance to fly, but it did. CHEST got involved early on, and then a big a group of people, including Tobacco Free Kids, the American Cancer Society, and many others in the public health space, got involved. CHEST represented the public health community during part of the negotiations that led to the Attorney General’s Master Settlement. We should be very proud of the role CHEST played in this critical public health effort. If I can look back at my time spent in CHEST leadership, and see it as fondly as I do when I look back at my time just being a part of our CHEST Foundation, I will feel incredibly fulfilled.
 

What made you want to be President of CHEST?

I believe it is always important to give back to the people who gave you something. CHEST has given me a ton over the last 36 years, so giving back to CHEST is easy.
 

What are you looking forward to as President of CHEST?

On a personal level, I am looking forward to what we are doing right now, meeting new people, and learning from young people.

Because of my background and upbringing, I have a passion for diversity and inclusion; I think we need to continue to talk about, learn about, care about, be open about, and be transparent about diversity of thought, inclusion, and care disparity. The word “diversity” means something different to every person, and, for that, we have to have respect.

As Dr. Studdard prepares to take on his new role in CHEST leadership this October, he is optimistic about what the future will bring and about the things that he will learn. He considers himself incredibly lucky to be in the position that he is in, and he values each relationship he has made during his involvement with CHEST. He is looking forward to all that is in store during his time as President. He left us with a quote from Wyatt Cooper:

“The only immortality we can be sure of is that part of ourselves we invest in others—the contribution we make to the totality of man, the knowledge we have shared, the truths we have found, the causes we have served, the lessons we have lived.”

John Studdard, MD, FCCP, has been a member of the American College of Chest Physicians for 36 years, and, this November, he will be inaugurated as CHEST President. This will not be Dr. Studdard’s first time in a presidential role for CHEST, as he served as CHEST Foundation President in 2013 and 2014. Currently, Dr. Studdard serves as a pulmonologist at Jackson Pulmonary in Jackson, Mississippi. Being a physician and being as heavily involved with an organization as Dr. Studdard is takes a lot of prioritizing, hard work, and dedication. Get to know CHEST’s new President through this interview.

Born and raised in Mississippi, Dr. Studdard says there were four factors that inspired him to become a physician:

1. I have always loved people and working with them, and I always admired the respect that physicians received in my community.

What are some of the biggest challenges you have encountered throughout your career?

Private practice makes you gain more independence and autonomy; you have to become more agile, more efficient, and you have awfully big workloads. However, you give up the academic stimulation of being in an academic center. It is a tough discipline in the private practice of medicine to try to stay up to date. Whether going to the CHEST Annual Meeting, reading our journal CHEST, or looking at CHEST education online products, those of us in the clinical practice of pulmonary, critical care, and sleep medicine are more dependent than any group on what our clinical educators write and teach.
 

How do/did you balance work and your personal life?

We are busy in practice, particularly when taking on volunteer opportunities, and that time comes out of something: time with family, hobbies, it has to come from somewhere. But it is not unique to those of us in medicine. My daughter is a 33-year-old mother to a 20-month-old beautiful granddaughter of ours and is pregnant with another child, and she and her husband both work full time. Our son and his wife also both work and must find ways to balance work/life issues. So work-life balance, particularly in today’s world, is more difficult than ever for everyone. I am blessed that my wife is the daughter of a general surgeon, and she understood a little bit about stressors in a physician’s life – sometimes she seems to understand more than others—she is a unique person. Work-life balance is all about priorities – our priority was our family. We spent a ton of time with our children, great vacations, rarely missed a program or ballgame (there were lots of them), and frequently that involved going to work early in the morning, coming home early in the evening, and going back to the hospital to finish up late at night. A lot of being a good parent is being lucky. We either did a lot of things right, or were lucky, or a combination of both, because I think our kids turned out pretty darn well.
 

What has been your favorite project throughout your involvement with CHEST?

Early in my days as a member of CHEST, a mentor of mine from training at the Mayo Clinic, Dr. Doug Gracey, gave me the opportunity to join the CHEST Government Relations Committee, which he chaired. After a few years, I was given the opportunity to serve as its Chair. We became heavily involved in the tobacco wars, as some people called them. Our Attorney General in Mississippi at the time, Mike Moore, and a plaintiff’s attorney in Mississippi, Dick Scruggs, whom I knew from some work I had done from the defense side of asbestos litigation, took a lead role in the Attorney General’s Master Settlement - a group of attorney generals suing the tobacco industry (basically, state’s Medicaid was suing the tobacco industry for reimbursement of funds). It was a completely different approach. The tobacco industry turned its nose up at it at first – they did not think it had a chance to fly, but it did. CHEST got involved early on, and then a big a group of people, including Tobacco Free Kids, the American Cancer Society, and many others in the public health space, got involved. CHEST represented the public health community during part of the negotiations that led to the Attorney General’s Master Settlement. We should be very proud of the role CHEST played in this critical public health effort. If I can look back at my time spent in CHEST leadership, and see it as fondly as I do when I look back at my time just being a part of our CHEST Foundation, I will feel incredibly fulfilled.
 

What made you want to be President of CHEST?

I believe it is always important to give back to the people who gave you something. CHEST has given me a ton over the last 36 years, so giving back to CHEST is easy.
 

What are you looking forward to as President of CHEST?

On a personal level, I am looking forward to what we are doing right now, meeting new people, and learning from young people.

Because of my background and upbringing, I have a passion for diversity and inclusion; I think we need to continue to talk about, learn about, care about, be open about, and be transparent about diversity of thought, inclusion, and care disparity. The word “diversity” means something different to every person, and, for that, we have to have respect.

As Dr. Studdard prepares to take on his new role in CHEST leadership this October, he is optimistic about what the future will bring and about the things that he will learn. He considers himself incredibly lucky to be in the position that he is in, and he values each relationship he has made during his involvement with CHEST. He is looking forward to all that is in store during his time as President. He left us with a quote from Wyatt Cooper:

“The only immortality we can be sure of is that part of ourselves we invest in others—the contribution we make to the totality of man, the knowledge we have shared, the truths we have found, the causes we have served, the lessons we have lived.”

Don’t forget how valuable the Vascular Educational and Self-Assessment Program can be in keeping with all things vascular-related. And the mobile app (Apple products only) for off-line use is expected to be available within days.

The fourth edition launched just two months ago. Besides the app, VESAP4 also offers syncing between the companion app and desktop version; expanded bookmarking and annotation, easier navigation and simplified tracking of CME/MOC certificates.

Costs are $450 for candidates, $550 for members and $650 for non-members. A total of 75 CME (7.5 for each of the 10 sections) will be available. For information, email [email protected] or call 800-258-7188. 

Don’t forget how valuable the Vascular Educational and Self-Assessment Program can be in keeping with all things vascular-related. And the mobile app (Apple products only) for off-line use is expected to be available within days.

The fourth edition launched just two months ago. Besides the app, VESAP4 also offers syncing between the companion app and desktop version; expanded bookmarking and annotation, easier navigation and simplified tracking of CME/MOC certificates.

Costs are $450 for candidates, $550 for members and $650 for non-members. A total of 75 CME (7.5 for each of the 10 sections) will be available. For information, email [email protected] or call 800-258-7188. 

Don’t forget how valuable the Vascular Educational and Self-Assessment Program can be in keeping with all things vascular-related. And the mobile app (Apple products only) for off-line use is expected to be available within days.

The fourth edition launched just two months ago. Besides the app, VESAP4 also offers syncing between the companion app and desktop version; expanded bookmarking and annotation, easier navigation and simplified tracking of CME/MOC certificates.

Costs are $450 for candidates, $550 for members and $650 for non-members. A total of 75 CME (7.5 for each of the 10 sections) will be available. For information, email [email protected] or call 800-258-7188. 

The SVS Foundation highlights innovation and the connection between research bench and patient bedside in its just-published 2017 Annual Report, now available online.

Read about the Foundation’s expanded mission, emphasizing disease prevent and patient education along with the core commitment to fund basic and clinical research. Read why Michael C. Dalsing, MD, gives and how Ulka Sachdev, MD, has utilized her Foundation awards to try to unlock the suffering caused by chronic venous insufficiency. Read about this year’s grant recipients, Foundation financial details, lists of donors to not only the Foundation but also the new Alexander Clowes Lecture Fund, award opportunities and how every gift helps. Read, and donate today.

The SVS Foundation highlights innovation and the connection between research bench and patient bedside in its just-published 2017 Annual Report, now available online.

Read about the Foundation’s expanded mission, emphasizing disease prevent and patient education along with the core commitment to fund basic and clinical research. Read why Michael C. Dalsing, MD, gives and how Ulka Sachdev, MD, has utilized her Foundation awards to try to unlock the suffering caused by chronic venous insufficiency. Read about this year’s grant recipients, Foundation financial details, lists of donors to not only the Foundation but also the new Alexander Clowes Lecture Fund, award opportunities and how every gift helps. Read, and donate today.

The SVS Foundation highlights innovation and the connection between research bench and patient bedside in its just-published 2017 Annual Report, now available online.

Read about the Foundation’s expanded mission, emphasizing disease prevent and patient education along with the core commitment to fund basic and clinical research. Read why Michael C. Dalsing, MD, gives and how Ulka Sachdev, MD, has utilized her Foundation awards to try to unlock the suffering caused by chronic venous insufficiency. Read about this year’s grant recipients, Foundation financial details, lists of donors to not only the Foundation but also the new Alexander Clowes Lecture Fund, award opportunities and how every gift helps. Read, and donate today.